Home > Signal Pathway > AMQUAR单克隆抗体抑制剂 > AMQUAR 单克隆抗体抑制剂

AMQUAR 单克隆抗体抑制剂


  • Ranibizumab MA1038

    Ranibizumab, a humanized, affinity-matured VEGF antibody fragment that neutralizes all isoforms of VEGF, is approved for use in ophthalmology.

    More
  • Rituximab MA1039

    Rituximab, a monoclonal antibody directed at CD20 positive B-lymphocytes, is the first-line treatment of acquired thrombotic thrombocytopenic purpura.

    More
  • Muromonab—CD3 MA1029

    Muromonab CD3 (OKT3), the murine anti-CD3 monoclonal antibody of the IgG-2a class, used as a powerful immunosuppressive agent in solid organ transplantation and the first-line treatment of acute allograft rejection.

    More
  • Natalizumab MA1030

    Natalizumab is a humanized monoclonal antibody against α4 integrins highly effective in relapsing-remitting multiple sclerosis (MS).

    More
  • Efalizumab MA1021

    Efalizumab, a recombinant humanized monoclonal IgG1 antibody directed against a subunit (CD11a) of leukocyte function-associated antigen-1 (LFA-1), inhibits the T cell activation, migration and adhesion to keratinocytes.

    More
  • Current page3, Total Pages8, Total Record38 First Prev 12345 Next Last Goto